CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-03 | Chang David D President and CEO | Sale | −46,003 | $1.68 | $77K | 5,317,237 |
| 2025-02-03 | Roberts Zachary EVP of R&D | Sale | −18,832 | $1.70 | $32K | 643,135 |
| 2025-01-24 | Douglas Earl Martin SVP, General Counsel | Grant or award | +144,928 | 594,252 | ||
| 2025-01-24 | Douglas Earl Martin SVP, General Counsel | Grant or award · Stock Option (Right to buy) | +512,370 | 512,370 | ||
| 2025-01-24 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award | +173,913 | 1,305,901 | ||
| 2025-01-24 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to buy) | +614,844 | 614,844 | ||
| 2025-01-24 | Yoshiyama Annie SVP, Finance | Grant or award | +36,232 | 137,990 | ||
| 2025-01-24 | Yoshiyama Annie SVP, Finance | Grant or award · Stock Option (Right to buy) | +128,093 | 128,093 | ||
| 2025-01-24 | Roberts Zachary EVP of R&D | Grant or award | +173,913 | 661,967 | ||
| 2025-01-24 | Roberts Zachary EVP of R&D | Grant or award · Stock Option (Right to buy) | +614,844 | 614,844 | ||
| 2025-01-24 | Belldegrun Arie Director | Grant or award | +369,957 | 2,236,816 | ||
| 2025-01-24 | Belldegrun Arie Director | Grant or award · Stock Option (Right to buy) | +1,307,927 | 1,307,927 | ||
| 2025-01-24 | Chang David D President and CEO | Grant or award | +552,174 | 5,363,240 | ||
| 2025-01-24 | Chang David D President and CEO | Grant or award · Stock Option (Right to buy) | +1,952,130 | 1,952,130 | ||
| 2025-01-21 | Roberts Zachary EVP of R&D | Sale | −27,199 | $1.78 | $48K | 488,054 |
| 2024-12-09 | MESSEMER DEBORAH M. Director | Sale 10b5-1 | −9,136 | $2.18 | $20K | 157,629 |
| 2024-12-05 | Humer Franz B Director | Sale | −9,221 | $2.16 | $20K | 307,507 |
| 2024-10-21 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −36,404 | $2.84 | $103K | 1,131,988 |
| 2024-08-21 | Douglas Earl Martin SVP, General Counsel | Shares withheld for taxes | −28,310 | $2.79 | $79K | 449,324 |
| 2024-06-18 | MESSEMER DEBORAH M. Director | Sale 10b5-1 | −18,641 | $2.28 | $42K | 166,765 |
Page 4 of 18 · 348 trades